Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen,4-hydroxytamoxifen and endoxifen, in breast cancer cells

Drug Metabolism and Disposition

Volumn 43, Issue 6, 2015, Pages 889-897

  Chanawong, Apichaya ^a   Hu, Dong Gui ^a   Meech, Robyn ^a   Mackenzie, Peter I ^a   McKinnon, Ross A ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ENDOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GLUCURONOSYLTRANSFERASE; RALOXIFENE; SMALL INTERFERING RNA; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA, HUMAN; ESTROGEN RECEPTOR ANTAGONIST; NEW DRUG; TAMOXIFEN; TUMOR PROTEIN; UDP-GLUCURONOSYLTRANSFERASE 2B15, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GLUCURONIDATION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MCF 7 CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UGT2B15 GENE; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; ENZYME INDUCTION; ENZYME SPECIFICITY; FEMALE; GENETICS; METABOLISM; MUTATION; REPORTER GENE; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUGS, INVESTIGATIONAL; ENZYME INDUCTION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ANTAGONISTS; FEMALE; GENES, REPORTER; GLUCURONOSYLTRANSFERASE; HUMANS; MCF-7 CELLS; MUTATION; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TAMOXIFEN;

EID: 84940389286     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062935     Document Type: Article

References (54)

1. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta K.L., Soiland H., Gjerde J, Garne JP, Rosenberg C.L., Silliman RA, and Sorensen HT, et al. (2011) Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev 20:1937-1943.
2. Ahmad A, Ali SM, Ahmad M.U., Sheikh S., and Ahmad I (2010a) Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat 122:579-584.
3. Ahmad A, Shahabuddin S, Sheikh S., Kale P, Krishnappa M, Rane R.C., and Ahmad I (2010b) Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 88:814-817.
4. Becker M, Sommer A, Krätzschmar JR, Seidel H., Pohlenz HD, and Fichtner I (2005) Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4:151-168.
5. Blevins-Primeau A.S., Sun D, Chen G., Sharma AK, Gallagher CJ, Amin S, and Lazarus P (2009) Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69:1892-1900.
6. Borges S, Desta Z, Li L., Skaar TC, Ward BA, Nguyen A, Jin Y., Storniolo AM, Nikoloff DM, and Wu L, et al. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80: 61-74.
7. Brooks JD, Teraoka SN, Malone K.E., Haile RW, Bernstein L, Lynch CF, Mellemkjaer L, Duggan D.J., Reiner AS, and Concannon P, et al. (2013) Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet 4:35-48.
8. Burstein HJ, Temin S, Anderson H., Buchholz TA, Davidson NE, Gelmon KE, Giordano S.H., Hudis CA, Rowden D, and Solky AJ, et al. (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255-2269.
9. Carroll JS, Meyer CA, Song J, Li W., Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton E.K., Fertuck KC, and Hall GF, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289-1297.
10. Chakraborty S and Biswas PK (2014) Structural insights into selective agonist actions of ta-moxifen on human estrogen receptor alpha. J Mol Model 20:2338.
11. Chang M (2012) Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) 20:256-267.
12. Dehal SS and Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406.
13. Deschênes J., Bourdeau V, White J.H., and Mader S (2007) Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences. J Biol Chem 282:17335-17339.
14. Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, and van de Velde CJ, et al. (2013) CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat 140:363-373.
15. Frasor J, Stossi F, Danes J.M., Komm B., Lyttle CR, and Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533.
16. Furr BJ and Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205.
17. Greer AK, Dates CR, Starlard-Davenport A, Edavana V.K., Bratton SM, Dhakal IB, Finel M, Kadlubar S.A., and Radominska-Pandya A (2014) A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacoge-nomics of tamoxifen and its derivatives. Drug Metab Dispos 42:1392-1400.
18. Hu DG, Gardner-Stephen D, Severi G., Gregory PA, Treloar J, Giles GG, English D.R., Hopper JL, Tilley WD, and Mackenzie PI (2010) A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α, 17β-diol glucuronide. Mol Pharmacol 78:714-722.
19. Hu DG and Mackenzie PI (2009) Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. Mol Pharmacol 76:425-439.
20. Hu DG and Mackenzie PI (2010) Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells. Drug Metab Dispos 38:2105-2109.
21. Hu DG, Mackenzie PI, Lu L, Meech R., and McKinnon RA (2015) Induction of human UDP-glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells. Drug Metab Dispos [published ahead of print].
22. Jacolot F, Simon I, Dreano Y., Beaune P, Riche C, and Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919.
23. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
24. Johnson MD, Zuo H, Lee K.H., Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart D.A., and Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.
25. Johnston SR, Haynes BP, Smith I.E., Jarman M., Sacks NP, Ebbs SR, and Dowsett M (1993) Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342:1521-1522.
26. Jordan VC, Collins MM, Rowsby L, and Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316.
27. Kaku T, Ogura K, Nishiyama T., Ohnuma T, Muro K, and Hiratsuka A (2004) Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 67:2093-2102.
28. Katzenellenbogen BS (1991) Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83:1434-1435.
29. Katzenellenbogen BS, Norman MJ, Eckert R.L., Peltz SW, and Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119.
30. Katzenellenbogen JA, Carlson KE, and Katzenellenbogen BS (1985) Facile geometric isomeri-zation of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Biochem 22:589-596.
31. Lévesque E., Beaulieu M, Green M.D., Tephly TR, Bélanger A, and Hum DW (1997) Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7:317-325.
32. Lim YC, Desta Z, Flockhart D.A., and Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478.
33. Lim YC, Li L, Desta Z., Zhao Q, Rae JM, Flockhart D.A., and Skaar TC (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503-512.
34. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
35. Malet C, Spritzer P, Cumins C., Guillaumin D, Mauvais-Jarvis P, and Kuttenn F (2002) Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol 82:289-296.
36. ∗2 polymorphisms in breast cancer patients. PLoS ONE 8:e72219.
37. Miller WR, Bartlett J, Brodie A.M., Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, and Sasano H, et al. (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13:829-837.
38. Nagaoka R, Iwasaki T, Rokutanda N., Takeshita A, Koibuchi Y, Horiguchi J., Shimokawa N, Iino Y, Morishita Y., and Koibuchi N (2006) Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine 30:261-268.
39. Nakamura A, Nakajima M, Yamanaka H., Fujiwara R, and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
40. Naundorf H, Becker M, Lykkesfeldt A.E., Elbe B., Neumann C, Büttner B, and Fichtner I (2000) Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer 82:1844-1850.
41. Nishiyama T, Ogura K, Nakano H., Ohnuma T, Kaku T, Hiratsuka A., Muro K, and Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830.
42. Nowell SA, Ahn J, Rae J.M., Scheys JO, Trovato A, Sweeney C, MacLeod S.L., Kadlubar FF, and Ambrosone CB (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258.
43. Ogura K, Ishikawa Y, Kaku T., Nishiyama T, Ohnuma T, Muro K., and Hiratsuka A (2006) Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71:1358-1369.
44. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
45. Osborne CK, Coronado E, Allred D.C., Wiebe V., and DeGregorio M (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482.
46. Seth P, Krop I, Porter D., and Polyak K (2002) Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene 21:836-843.
47. Sun D, Chen G, Dellinger R.W., Duncan K., Fang JL, and Lazarus P (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8:R50.
48. Sun D, Sharma AK, Dellinger R.W., Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T., Amin S, and Lazarus P (2007) Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35:2006-2014.
49. Teft WA, Mansell SE, and Kim RB (2011) Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 39:558-562.
50. Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA, and Arenas-Aranda D (2014) Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). review Oncol Rep 32:3-15.
51. Wegman P, Elingarami S, Carstensen J., Stål O, Nordenskjöld B, and Wingren S (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in post-menopausal patients with breast cancer. Breast Cancer Res 9:R7.
52. Williams ML, Lennard MS, Martin I.J., and Tucker GT (1994) Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cyto-chromes P450. Carcinogenesis 15:2733-2738.
53. Youlden DR, Cramb SM, Dunn N.A., Muller JM, Pyke CM, and Baade PD (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36:237-248.
54. Zheng Y, Sun D, Sharma A.K., Chen G., Amin S, and Lazarus P (2007) Elimination of anti-estrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35: 1942-1948.